George Perry to Neuroprotective Agents
This is a "connection" page, showing publications George Perry has written about Neuroprotective Agents.
Connection Strength
2.194
-
Plascencia-Villa G, Perry G. Status and future directions of clinical trials in Alzheimer's disease. Int Rev Neurobiol. 2020; 154:3-50.
Score: 0.603
-
Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics. 2019 07; 16(3):666-674.
Score: 0.561
-
Plascencia-Villa G, Perry G. Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. Antioxid Redox Signal. 2021 03 10; 34(8):591-610.
Score: 0.151
-
Doens D, Valiente PA, Mfuh AM, X T Vo A, Tristan A, Carre?o L, Quijada M, Nguyen VT, Perry G, Larionov OV, Lleonart R, Fern?ndez PL. Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimer's Disease. ACS Chem Neurosci. 2017 06 21; 8(6):1232-1241.
Score: 0.119
-
Putta S, Yarla NS, Peluso I, Tiwari DK, Reddy GV, Giri PV, Kumar N, Malla R, Rachel V, Bramhachari PV, Reddy D RS, Bade R, Mannarapu M, Barreto GE, Lu DY, Tarasov VV, Chubarev VN, Ribeiro FF, Scotti L, Scotti MT, Kamal MA, Ashraf GM, Aliev G, Perry G, Sarker SD, Rao CV, Bishayee A. Anthocyanins: Multi-Target Agents for Prevention and Therapy of Chronic Diseases. Curr Pharm Des. 2017; 23(41):6321-6346.
Score: 0.118
-
Gerenu G, Liu K, Chojnacki JE, Saathoff JM, Mart?nez-Mart?n P, Perry G, Zhu X, Lee HG, Zhang S. Curcumin/melatonin hybrid 5-(4-hydroxy-phenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide ameliorates AD-like pathology in the APP/PS1 mouse model. ACS Chem Neurosci. 2015 Aug 19; 6(8):1393-1399.
Score: 0.105
-
Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl Psychiatry. 2013 Dec 03; 3:e332.
Score: 0.095
-
Correia SC, Cardoso S, Santos RX, Carvalho C, Santos MS, Perry G, Smith MA, Moreira PI. New insights into the mechanisms of mitochondrial preconditioning-triggered neuroprotection. Curr Pharm Des. 2011; 17(31):3381-9.
Score: 0.078
-
Lee HP, Casadesus G, Zhu X, Lee HG, Perry G, Smith MA, Gustaw-Rothenberg K, Lerner A. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother. 2009 Nov; 9(11):1615-21.
Score: 0.072
-
Lee HG, Zhu X, Takeda A, Perry G, Smith MA. Emerging evidence for the neuroprotective role of alpha-synuclein. Exp Neurol. 2006 Jul; 200(1):1-7.
Score: 0.057
-
Moreira PI, Oliveira CR, Santos MS, Nunomura A, Honda K, Zhu X, Smith MA, Perry G. A second look into the oxidant mechanisms in Alzheimer's disease. Curr Neurovasc Res. 2005 Apr; 2(2):179-84.
Score: 0.052
-
Takata K, Kitamura Y, Kakimura J, Shibagaki K, Taniguchi T, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Possible protective mechanisms of heme oxygenase-1 in the brain. Ann N Y Acad Sci. 2002 Nov; 977:501-6.
Score: 0.044
-
Pappolla MA, Simovich MJ, Bryant-Thomas T, Chyan YJ, Poeggeler B, Dubocovich M, Bick R, Perry G, Cruz-Sanchez F, Smith MA. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res. 2002 Apr; 32(3):135-42.
Score: 0.042
-
Jarero-Basulto JJ, Luna-Mu?oz J, Mena R, Kristofikova Z, Ripova D, Perry G, Binder LI, Garcia-Sierra F. Proteolytic cleavage of polymeric tau protein by caspase-3: implications for Alzheimer disease. J Neuropathol Exp Neurol. 2013 Dec; 72(12):1145-61.
Score: 0.024
-
Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006 Jul; 65(7):631-41.
Score: 0.014
-
Zhu X, Smith MA, Perry G, Wang Y, Ross AP, Zhao HW, Lamanna JC, Drew KL. MAPKs are differentially modulated in arctic ground squirrels during hibernation. J Neurosci Res. 2005 Jun 15; 80(6):862-8.
Score: 0.013
-
Marlatt MW, Webber KM, Moreira PI, Lee HG, Casadesus G, Honda K, Zhu X, Perry G, Smith MA. Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem. 2005; 12(10):1137-47.
Score: 0.013
-
Webber KM, Bowen R, Casadesus G, Perry G, Atwood CS, Smith MA. Gonadotropins and Alzheimer's disease: the link between estrogen replacement therapy and neuroprotection. Acta Neurobiol Exp (Wars). 2004; 64(1):113-8.
Score: 0.012
-
Kakimura J, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J. 2002 Apr; 16(6):601-3.
Score: 0.011
-
Zhou F, Zhu X, Castellani RJ, Stimmelmayr R, Perry G, Smith MA, Drew KL. Hibernation, a model of neuroprotection. Am J Pathol. 2001 Jun; 158(6):2145-51.
Score: 0.010